Rankings
▼
Calendar
XLO (Xilio Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
XLO
Xilio Therapeutics, Inc.
Mkt Cap
$28M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$32M
Net Income (TTM)
-$58M
EPS (TTM)
-$0.65
Free Cash Flow (TTM)
-$18M
Gross Margin
50.7%
Op. Margin
-137.6%
Net Margin
-183.9%
FCF Margin
-55.3%
P/S Ratio (TTM)
0.9x
P/E Ratio (TTM)
—
YoY Rev Growth
+588.4%
Employees
—
Earnings Reports
▶
Q3 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q4 22
$0
$0
-$23M
Q1 23
$0
$0
-$24M
Q2 23
$0
-$492K
-$20M
Q3 23
$0
$0
-$17M
Q4 23
$0
-$449K
-$18M
Q1 24
$0
$0
-$17M
Q2 24
$2M
$2M
-$15M
Q3 24
$2M
$2M
-$15M
Q4 24
$2M
$2M
-$14M
Q1 25
$3M
$3M
-$14M
Q2 25
$8M
-$7M
-$14M
Q3 25
$19M
$19M
-$2M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q4 22
—
—
Q1 23
—
—
Q2 23
—
—
Q3 23
—
—
Q4 23
—
—
Q1 24
—
—
Q2 24
12.1x
—
Q3 24
6.2x
—
Q4 24
4.5x
—
Q1 25
3.1x
—
Q2 25
1.9x
—
Q3 25
0.9x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q4 22
-$18M
-$19M
Q1 23
-$25M
-$25M
Q2 23
-$17M
-$17M
Q3 23
-$13M
-$13M
Q4 23
-$13M
-$13M
Q1 24
-$11M
-$11M
Q2 24
$20M
$20M
Q3 24
-$14M
-$14M
Q4 24
-$14M
-$14M
Q1 25
$29M
$29M
Q2 25
-$14M
-$15M
Q3 25
-$17M
-$17M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q4 22
$509K
Q1 23
$170K
Q2 23
$316K
Q3 23
$0
Q4 23
$0
Q1 24
$0
Q2 24
$21K
Q3 24
$9K
Q4 24
$6K
Q1 25
$22K
Q2 25
$401K
Q3 25
$0
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q4 22
—
+18.5%
Q1 23
—
+10.8%
Q2 23
—
-18.1%
Q3 23
—
-14.1%
Q4 23
—
-21.7%
Q1 24
—
-25.7%
Q2 24
—
-15.2%
Q3 24
—
-1.9%
Q4 24
—
-15.3%
Q1 25
—
-4.0%
Q2 25
+243.0%
+31.6%
Q3 25
+742.5%
+23.3%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q4 22
$2M
—
Q1 23
$2M
—
Q2 23
$2M
—
Q3 23
$2M
—
Q4 23
$0
—
Q1 24
$2M
—
Q2 24
$2M
64.1%
Q3 24
$2M
69.6%
Q4 24
$2M
87.9%
Q1 25
$2M
52.4%
Q2 25
$1M
16.7%
Q3 25
$0
0.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q4 22
$15M
$8M
—
Q1 23
$16M
$7M
—
Q2 23
$13M
—
$6M
Q3 23
$11M
$6M
—
Q4 23
$12M
—
$6M
Q1 24
$10M
$6M
—
Q2 24
$11M
$6M
—
Q3 24
$11M
$6M
—
Q4 24
$9M
$7M
—
Q1 25
$8M
$9M
—
Q2 25
$15M
$7M
—
Q3 25
$14M
—
$6M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q4 22
$120M
$0
$120M
Q1 23
$93M
$0
$93M
Q2 23
$75M
$0
$75M
Q3 23
$60M
$0
$60M
Q4 23
$45M
$0
$45M
Q1 24
$34M
$0
$34M
Q2 24
$75M
$0
$75M
Q3 24
$61M
$0
$61M
Q4 24
$55M
$0
$55M
Q1 25
$89M
$0
$89M
Q2 25
$122M
$0
$122M
Q3 25
$104M
$0
$104M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q4 22
27M
+0.1%
Q1 23
27M
+0.1%
Q2 23
27M
+0.1%
Q3 23
28M
+0.2%
Q4 23
28M
+0.1%
Q1 24
28M
+1.3%
Q2 24
58M
+106.9%
Q3 24
63M
+9.9%
Q4 24
65M
+1.9%
Q1 25
75M
+15.5%
Q2 25
96M
+29.1%
Q3 25
144M
+49.4%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 19
—
—
FY 20
—
—
FY 21
$0
74
FY 22
$0
89
FY 23
$0
73
FY 24
$99K
64
marketcaparena.com